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Is prostate cancer different in black men? This is the question that Tsodikov and colleagues are trying to answer in their
study published in this issue of Cancer.1 Their findings highlight some important racial differences in screening patterns
and projected outcomes that suggest a more personalized approach to prostate cancer screening that is not “1 size fits all.”
Indeed, a more personalized approach to screening among black men would be an active move toward precision medicine
that does not require the sequencing of germline or somatic DNA.
To inform this question, the authors used predictive modeling techniques to compare the natural history of prostate
cancer among black men compared with the general population. To do this, they reconstructed prostate-specific antigen
(PSA) screening patterns in the United States and then fit 3 independent simulation models using screening data from the
National Health Interview Survey and prostate cancer incidence data from the Surveillance, Epidemiology, and End
Results (SEER) database. They observed that from 30% to 43% of black men develop preclinical prostate cancer by age
85 years, a risk that is 28% to 56% higher than that in the general population. The models predicted similar risks of pros-
tate cancer diagnosis when comparing black men with men in the general population (range, 35%-49%). Black men, how-
ever, were much more likely (range, 44%-75%) to progress to metastatic prostate cancer before diagnosis compared with
men in the general population.
Their study is timely, as the US Preventive Services Task Force (USPSTF) is currently reviewing their 2012 grade D
recommendation against PSA screening2 and is expected to release an updated recommendation sometime in 2017. One
of the key issues highlighted in the research plan released as part of the review is evaluating whether the effectiveness of
PSA screening varies by subpopulation or risk factor, including age, race/ethnicity, family history, and clinical risk assess-
ment.3 The 2012 USPSTF prostate cancer screening recommendations do not currently take into account race/ethnicity;
the grade D recommendation against screening applies to men of all races.2 The appropriateness of these recommenda-
tions for higher-risk men, including black men, continues to be debated in the medical literature and in the media.4-6 In
addition, the clinical guidelines in this area are not aligned when it comes to screening black men. Although the American
Urological Association and National Comprehensive Cancer Network guidelines both reference that African American
race is a strong risk factor for prostate cancer and that screening discussions should be individualized,7,8 the guidelines fall
short of providing explicit guidance on incorporating race/ethnicity into screening recommendations and discussions.
The American Cancer Society guidelines are the only ones that currently make specific screening recommendations for
black men. They recommend offering PSA screening to black men beginning at age 45 years.9 Therefore, a lack of clarity
continues around the appropriateness of using PSA to screen for prostate cancer in black men.
What is clear, however, is that prostate cancer disproportionally affects black men. In 2016 alone, 1 in 6 black men
were diagnosed with prostate cancer, and 1 in 23 died from their disease.10 Black men are more likely to be diagnosed
with prostate cancer at a younger age and a higher stage and to have their disease progress after treatment compared with
white men.10 Although the incidence andmortality rates of prostate cancer in the United States have been steadily decreas-
ing over time, black men continue to remain significantly more likely to die from their prostate cancer.10 The lifetime
probability of a black man dying of prostate cancer is almost double that of a non-Hispanic white man (4.4% vs 2.4%).10
This is not new news. African American race is 1 of the strongest and most established risk factors for prostate cancer
diagnosis and death. A wealth of literature exists in this area and has spawned myriad studies aimed at elucidating the
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underlying causes of these disparities, including sociode-
mographics, genetics, environmental factors, health
behaviors, differences in tumor biology, access to care
issues, and variations in screening, detection, treatment,
and post-treatment surveillance.6,11 And yet there remains
a lack of data on the effectiveness of prostate cancer
screening in black men. It is well established that black
men are under-represented in clinical trials of prostate
cancer.12 In the 2 large, randomized controlled trials of
prostate cancer screening on which the USPSTF based
their recommendations,13,14 the proportion of black men
included was extremely low. In the Prostate, Lung, Colo-
rectal, and Ovarian Cancer Screening Trial, only 4% of
the study population was African American. Although the
European Randomized Study of Screening for Prostate
Cancer did not publish their race data, the countries
included were mostly Caucasian.6,14 Given the lack of
prospective screening data in black men, additional obser-
vational studies that include more diverse populations are
necessary to inform future screening strategies.
In addition, further consideration of more tailored
prostate cancer screening guidelines is urgently needed.
Recently, multiple studies suggest that the 2012 USPSTF
guidelines have resulted in a marked decrease in PSA
screening rates in the United States. These decreases in
screening rates have been observed among all age
ranges.15-17 In addition, studies have noted decreases in
the rates of diagnosis of early stage disease.16,18 Disturb-
ingly, early data suggest there may be an increase in high-
risk disease,19 but use associated with PSA, including sub-
sequent referrals, urology visits, and treatments, may not
have changed much.17,20 Although it is possible that this
may be because of the more discriminate use of PSA
screening among men who physicians believe are most
likely to benefit from early detection, it is concerning that
the current recommendations may result in decreased
screening and diagnosis rates in higher-risk men who are
most likely to benefit from early detection and to require
subsequent treatment.
It is noteworthy that the impact of these recommen-
dations on metastatic and mortality rates still remains
largely unknown. Using predictive modeling approaches,
Gulati and colleagues previously estimated that, by elimi-
nating PSA screening, the number of patients with meta-
static disease would double, and the mortality rate would
increase from 13% to 25% by 2025.21 Two recent studies
suggest that the incidence of later stage or metastatic dis-
ease may be increasing since the release of the recommen-
dations, particularly in younger men.22,23 However,
because prostate cancer takes years to progress in most
men, it is still too soon to fully appreciate the impact of
the guidelines on the rates of metastatic prostate cancer
and prostate cancer death. If the wide deimplementation
of PSA screening does turn out to increase metastatic and
fatal prostate cancer rates in the United States, then it is
likely that this burden will disproportionately affect black
men. Therefore, data to inform policy discussions regard-
ing whether or not PSA screening guidelines should differ
for black men, as presented in this issue of Cancer, are
important.
The results reported by Tsodikov and colleagues fur-
ther inform the ongoing discussion about whether or not
screening practices in black men need to be adapted to
better align with the finding that they are much more like-
ly to progress to metastatic disease and subsequently die
from their cancer.1 In light of the findings from their
study, the authors question whether or not it is time to
consider alternative screening approaches specifically in
black men. However, there are some potential limitations
to their study that warrant consideration when interpret-
ing the results. The use of predictive modeling has inher-
ent limitations, including the reliance on the assumption,
in this case, that prostate cancer is progressive. This
resulted in the exclusion from these models of indolent
prostate cancers, which make up a large proportion of the
prostate cancers diagnosed as a result of PSA screening.
However, the authors did use 3 different modeling strate-
gies that relied on various assumptions in an effort to
increase the robustness of their results. In addition, the
data used to reconstruct PSA screening were retrospective,
and age at first PSA was self-reported from the 2005
National Health Interview Survey, which was then com-
bined with claims from SEER-Medicare to estimate the
intervals between screening tests. The older patients in
SEER-Medicare may also have had screening intervals
that differ from those in younger men, which is relevant,
because the authors’ recommendations about the policy
implications of their work focus on screening black men
at younger ages.
At the end of the day, however, the findings from
this study suggest that the risk/benefit tradeoffs of PSA
screening may be quite different for black men compared
with men in the general population. Therefore, whether
current general population PSA screening guidelines
should apply to this high-risk group warrants further poli-
cy consideration. Given the issues of overdiagnosis and
treatment of indolent prostate cancer that arose from prior
ubiquitous screening practices, any recommendations to
change current screening approaches need to be carefully
considered and based on empirical evidence. Although
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more evidence on the downstream mortality effects of
PSA screening in black men would be ideal to inform
these policies, it is worth contemplating whether we have
now reached a critical tipping point in PSA screening for
black men. In the growing era of precision medicine and
personalized health initiatives, it is important that we con-
sider that precision medicine approaches can be applied
more broadly than the use genetic or genomic data. These
approaches can be applied to better tailor screening practi-
ces to men who will indeed benefit from early detection of
prostate cancer. Because the evidence is accumulating that
a 1-size-fits-all screening approach to prostate cancer may
not be what is most appropriate, it may be time for the
conversation around PSA screening to really focus on
more personalized approaches to screening in high-risk
black men.
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